Evidence map›Paper›PMID 19229108›Full record

ArticleThe Journal of clinical investigation2009

Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

Yi Lai, Gail D Thomas, Yongping Yue, Hsiao T Yang, Dejia Li, Chun Long, Luke Judge, Brian Bostick, Jeffrey S Chamberlain, Ronald L Terjung and 1 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06290713 (Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy), which is not on this map. Cited by 232 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
232citing papers in PubMed, 2 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06290713 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)

TypeinterventionalSponsorUniversity of FloridaRan2024 to 2026Enrolled50ConditionsDuchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in ChildrenArmsTadalafil, Placebo, Exercise Training
3 · Its place in the literature

Who cites it

232 citing papers in PubMed, 2 syntheses or guidelines pooled it, 378 citations in OpenAlex.

  1. Pooled it
  2. WHOLE-BODY VIBRATION EXERCISE IS WELL TOLERATED IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2017
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. AAVcc47-The Yale journal of biology and medicine · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  17. Skeletal muscle disorders as risk factors for type 2 diabetes.Molecular and cellular endocrinology · 2025
    Review
  18. Review
  19. Article
  20. Article

172 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Yi LaiDepartment of Molecular Microbiology and Immunology, University of Missouri, One Hospital Drive, Columbia, MO 65212, USA.
Gail D Thomas
Yongping Yue
Hsiao T Yang
Dejia Li
Chun Long
Luke Judge
Brian Bostick
Jeffrey S Chamberlain
Ronald L Terjung
Dongsheng Duan
University of Missouri · USUniversity of Washington · USMissouri College · USThe University of Texas Southwestern Medical Center · US

Funding

Dual AAV Vectors for Duchenne Muscular Dystrophy TherapyR01AR049419 · NIAMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI DUAN, DONGSHENG · 2003 to 2012
$4.1M
EXERCISE TRAINING AND PERIPHERAL ARTERIAL INSUFFICIENCYR01HL037387 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI TERJUNG, RONALD L · 1987 to 2004
$1.8M
Exploring systemic AAV gene delivery in the dystrophic dogR21AR057209 · NIAMS · UNIVERSITY OF MISSOURI-COLUMBIA · PI DUAN, DONGSHENG · 2008 to 2009
$372k
Expressing full-length dystrophin with AAVR21NS062934 · NINDS · UNIVERSITY OF MISSOURI-COLUMBIA · PI DUAN, DONGSHENG · 2008 to 2009
$360k
NHLBI NIH HHS HL 37387NHLBI NIH HHS R01 HL037387NIAMS NIH HHS AR 49419NIAMS NIH HHS AR 57209NIAMS NIH HHS R01 AR049419NIAMS NIH HHS R21 AR057209NINDS NIH HHS NS 62934NINDS NIH HHS R21 NS062934
6 · The paper itself

Abstract

Sarcolemma-associated neuronal NOS (nNOS) plays a critical role in normal muscle physiology. In Duchenne muscular dystrophy (DMD), the loss of sarcolemmal nNOS leads to functional ischemia and muscle damage; however, the mechanism of nNOS subcellular localization remains incompletely understood. According to the prevailing model, nNOS is recruited to the sarcolemma by syntrophin, and in DMD this localization is altered. Intriguingly, the presence of syntrophin on the membrane does not always restore sarcolemmal nNOS. Thus, we wished to determine whether dystrophin functions in subcellular localization of nNOS and which regions may be necessary. Using in vivo transfection of dystrophin deletion constructs, we show that sarcolemmal targeting of nNOS was dependent on the spectrin-like repeats 16 and 17 (R16/17) within the rod domain. Treatment of mdx mice (a DMD model) with R16/17-containing synthetic dystrophin genes effectively ameliorated histological muscle pathology and improved muscle strength as well as exercise performance. Furthermore, sarcolemma-targeted nNOS attenuated alpha-adrenergic vasoconstriction in contracting muscle and improved muscle perfusion during exercise as measured by Doppler and microsphere circulation. In summary, we have identified the dystrophin spectrin-like repeats 16 and 17 as a novel scaffold for nNOS sarcolemmal targeting. These data suggest that muscular dystrophy gene therapies based on R16/17-containing dystrophins may yield better clinical outcomes than the current therapies.

Indexed as

AnimalsBinding SitesDystrophinHumansMiceMice, Inbred mdxMuscle ContractionMuscular Dystrophy, AnimalMuscular Dystrophy, DuchenneNitric OxideNitric Oxide Synthase Type IPhysical Conditioning, AnimalSarcolemmaSpectrinVasoconstrictionDystrophinNitric OxideNitric Oxide Synthase Type ISpectrin

Identifiers

PMID19229108
PMCPMC2648692
OpenAlexW1990433203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.